AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10353670 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus infusion of 50 mg/kg tranexamic acid at the beginning of cardiopulmonary bypass (group A)
Number of subjects: 46
Study 10353670 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus infusion of 50 mg/kg tranexamic acid at the beginning of cardiopulmonary bypass and continuous infusion of 10 mg/kg per h for 6 h after cardiopulmonary bypass (group B)
Number of subjects: 46
Study 10353670 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 46
Study 8745671 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant radiotherapy with cisplatin (CDDP) 20 mg/m2, 5-fluorouracil (5-FU) 400 mg/m2 (day 1 to day 4), and mitomycin C (MMC) 10 mg/m2 (day 1) for three cycles at days 1, 21, and 42.
Number of subjects: 27
Study 8745671 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant radiotherapy with cisplatin (CDDP), 5-fluorouracil (5-FU), and mitomycin C (MMC).
Number of subjects: 27
Study 2330934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro drinking driving condition
Number of subjects: 36
Study 2330934 — intervention group
Group type: COMPARATOR
Intervention: Against drinking driving condition
Number of subjects: 36
Study 2330934 — intervention group
Group type: EXPERIMENTAL
Intervention: Male subjects
Number of subjects: 36
Study 2330934 — intervention group
Group type: EXPERIMENTAL
Intervention: Female subjects
Number of subjects: 36
Study 7028084 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlortetracycline eye ointment
Number of subjects: 85
Study 7028084 — intervention group
Group type: COMPARATOR
Intervention: 1% rifampicin eye ointment
Number of subjects: 85
Study 31834125 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability (VVV) in blood pressure (BP)
Number of subjects: 3091
Study 31834125 — intervention group
Group type: EXPERIMENTAL
Intervention: Coefficient of variation SBP
Number of subjects: 3091
Study 31834125 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard deviation (SD) or coefficient of variation DBP
Number of subjects: 3091
Study 31834125 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability in BP
Number of subjects: 3091
Study 31179916 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined center- and home-based intervention
Number of subjects: 444
Study 31179916 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based intervention only
Number of subjects: 444
Study 31179916 — intervention group
Group type: COMPARATOR
Intervention: Comparison (control group)
Number of subjects: 444
Study 28826645 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketorolac 20 mg
Number of subjects: 72
Study 28826645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 24867904 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current (IFC)
Number of subjects: 64
Study 24867904 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 64
Study 24867904 — intervention group
Group type: COMPARATOR
Intervention: Both IFC and TENS
Number of subjects: 64
Study 23998970 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning-dose group (20 mg controlled-release simvastatin in the morning, placebo in the evening)
Number of subjects: 132
Study 23998970 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening-dose group (placebo in the morning, 20 mg controlled-release simvastatin in the evening)
Number of subjects: 132
Study 23998970 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 132
Study 21832863 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray 0.1% (ANS)
Number of subjects: 244
Study 21832863 — intervention group
Group type: COMPARATOR
Intervention: Levocabastine nasal spray 0.05% (LNS)
Number of subjects: 244
Study 19286422 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine treatment plus radiotherapy
Number of subjects: 875
Study 19286422 — intervention group
Group type: COMPARATOR
Intervention: Endocrine treatment alone
Number of subjects: 875
Study 17403840 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide educational intervention (mailed newsletters and educational materials)
Number of subjects: 1106
Study 17403840 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1106
Study 17403840 — intervention group
Group type: EXPERIMENTAL
Intervention: Subanalysis for Medicaid-insured children
Number of subjects: 1106
Study 14651948 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization during an important viva voce examination (n=22)
Number of subjects: 45
Study 14651948 — intervention group
Group type: COMPARATOR
Intervention: Immunization during examination-free term time (n=23)
Number of subjects: 45
Study 10993641 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologically detectable bone lesions
Number of subjects: 51
Study 10993641 — intervention group
Group type: COMPARATOR
Intervention: No bone lesions
Number of subjects: 51
Study 10993641 — intervention group
Group type: EXPERIMENTAL
Intervention: MYCN amplification
Number of subjects: 51
Study 10993641 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary vanillylmandelic/homovanillic acid ratio
Number of subjects: 51
Study 10993641 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ferritin levels
Number of subjects: 51
Study 9063764 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 mg L-arginine and 1,500 mg L-lysine ingestion followed by resistance exercise (Trial B)
Number of subjects: 16
Study 9063764 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion followed by resistance exercise (Trial A)
Number of subjects: 16
Study 9063764 — intervention group
Group type: COMPARATOR
Intervention: 1,500 mg L-arginine and 1,500 mg L-lysine ingestion without exercise (Trial C)
Number of subjects: 16
Study 9063764 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion without exercise (Trial D)
Number of subjects: 16
Study 8366413 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic scaler plastic insert
Number of subjects: 23
Study 8366413 — intervention group
Group type: COMPARATOR
Intervention: Sonic metal insert
Number of subjects: 23
Study 8366413 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic plastic insert
Number of subjects: 23
Study 3101535 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15-1788 (0.5 to 2.0 mg)
Number of subjects: 38
Study 3101535 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15-1788 (0.3 to 0.8 mg)
Number of subjects: 38
Study 3101535 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15-1788
Number of subjects: 38
Study 30455091 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy interventions (manual therapy and exercise)
Number of subjects: 130
Study 30455091 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard physical therapy and trigger point dry needling
Number of subjects: 130
Study 30455091 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard physical therapy and sham trigger point dry needling
Number of subjects: 130
Study 29274471 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS)
Number of subjects: 24
Study 29274471 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 24
Study 26995298 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram, Sertraline, or Venlafaxine extended-release (8 weeks treatment)
Number of subjects: 1008
Study 26995298 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy participants (no medication or intervention)
Number of subjects: 1008
Study 25498992 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring (n=47); patients measured body weight, blood pressure, pulse, and answered symptom-related questions weekly, reporting to a heart failure nurse via a mobile app.
Number of subjects: 94
Study 25498992 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring (n=47); patients had increased health care resource use.
Number of subjects: 94
Study 25498992 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring (n=47); adherence rate was close to 90%.
Number of subjects: 94
Study 25498992 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring (n=47); technology feedback was collected.
Number of subjects: 94
Study 25498992 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=47); received multidisciplinary treatment according to standard practices.
Number of subjects: 94
Study 22749594 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine and/or 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 147
Study 22749594 — intervention group
Group type: COMPARATOR
Intervention: Non-splenectomized non-vaccinated control group
Number of subjects: 147
Study 22749594 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomized patients vaccinated
Number of subjects: 147
Study 20031392 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clodronate 1600 mg/d
Number of subjects: 851
Study 20031392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 851
Study 18765480 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 80
Study 18765480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15886667 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary amputation (African American patients)
Number of subjects: 513
Study 15886667 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat amputation (African American patients)
Number of subjects: 513
Study 12679835 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Nutritional Assessment (MNA)
Number of subjects: 43
Study 12679835 — intervention group
Group type: COMPARATOR
Intervention: Subjective Global Assessment (SGA)
Number of subjects: 43
Study 10864113 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot, humid air delivered by mask
Number of subjects: 18
Study 10864113 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot, humid air inhaled in a chamber
Number of subjects: 18
Study 8818092 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (n = 10)
Number of subjects: 20
Study 8818092 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia (n = 10)
Number of subjects: 20
Study 1424324 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 0
Study 1424324 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 3878719 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with lorazepam premedication
Number of subjects: 0
Study 3878719 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with papaveretum and hyoscine premedication
Number of subjects: 0
Study 3878719 — intervention group
Group type: COMPARATOR
Intervention: Unpremedicated patients
Number of subjects: 0
Study 3878719 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (with lignocaine 0.5 mg)
Number of subjects: 0
Study 3878719 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 31026742 — intervention group
Group type: EXPERIMENTAL
Intervention: COP-1 (copulations within the first 4 h after estrus)
Number of subjects: 48
Study 31026742 — intervention group
Group type: EXPERIMENTAL
Intervention: COP-2 (copulations around 16 h after estrus)
Number of subjects: 48
Study 31026742 — intervention group
Group type: COMPARATOR
Intervention: CON (noncopulations, only mounts)
Number of subjects: 48
Study 28704328 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (DXM) alone (20 mg IV)
Number of subjects: 86
Study 28704328 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) plus Hydrocortisone (HCT) (100 mg IV)
Number of subjects: 86
Study 25341431 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment, 30-min weekly for 3 weeks
Number of subjects: 15
Study 25341431 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment
Number of subjects: 15
Study 25341431 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 15
Study 23346948 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 660
Study 23346948 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 660
Study 23346948 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 660
Study 21255760 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V
Number of subjects: 1002
Study 21255760 — intervention group
Group type: COMPARATOR
Intervention: TAXUS
Number of subjects: 1002
Study 21255760 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V and TAXUS
Number of subjects: 1002
Study 19908310 — intervention group
Group type: COMPARATOR
Intervention: Placebo (DATATOP)
Number of subjects: 0
Study 19908310 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PRECEPT)
Number of subjects: 0
Study 19908310 — intervention group
Group type: COMPARATOR
Intervention: Placebo (DATATOP) vs Placebo (PRECEPT)
Number of subjects: 0
Study 16391584 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg (600 IU) vitamin D(3) and 1,500 mg calcium/day for 8 weeks
Number of subjects: 30
Study 16391584 — intervention group
Group type: COMPARATOR
Intervention: 1,500 mg calcium/day for 8 weeks (control group)
Number of subjects: 30
Study 15292721 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure on P6 point (Nei-Guan) for 5 minutes at least 3 times a day before chemotherapy and mealtimes
Number of subjects: 40
Study 15292721 — intervention group
Group type: COMPARATOR
Intervention: Regular antiemesis medication (Control group)
Number of subjects: 40
Study 11441413 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/m2 docetaxel for three cycles before definitive surgery or radiotherapy
Number of subjects: 274
Study 11441413 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction docetaxel followed by curative radiotherapy
Number of subjects: 274
Study 11441413 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel in combination with cisplatin or carboplatin
Number of subjects: 274
Study 9158047 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (20 mg/kg/day intravenously in 150 ml of saline for five days)
Number of subjects: 51
Study 9158047 — intervention group
Group type: COMPARATOR
Intervention: Placebo (150 ml of saline without POF)
Number of subjects: 51
Study 9158047 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 51
Study 8198036 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg plus hydrochlorothiazide 12.5 mg (group 2)
Number of subjects: 38
Study 8198036 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg (group 1)
Number of subjects: 38
Study 3681565 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care professional judgements of substance use
Number of subjects: 0
Study 3681565 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent self-reports of substance use
Number of subjects: 0
Study 2195345 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine (100 mg/ml, 5 ml, three times daily)
Number of subjects: 16
Study 2195345 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 16
Study 2195345 — intervention group
Group type: EXPERIMENTAL
Intervention: Vehicle (after switch to cyclosporine)
Number of subjects: 16
Study 31919134 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (taxane and anthracycline)
Number of subjects: 29
Study 31919134 — intervention group
Group type: COMPARATOR
Intervention: Residual cancer after neoadjuvant chemotherapy
Number of subjects: 29
Study 30850828 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet + 100 mg MEF/kg diet
Number of subjects: 180
Study 30850828 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet + 300 mg ECOS/kg diet
Number of subjects: 180
Study 30850828 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet + 100 mg MEF/kg diet + 300 mg ECOS/kg diet
Number of subjects: 180
Study 30850828 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet + 500 mg ECOS/kg diet
Number of subjects: 180
Study 30850828 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet + 100 mg MEF/kg diet + 500 mg ECOS/kg diet
Number of subjects: 180
Study 30850828 — intervention group
Group type: COMPARATOR
Intervention: Control group, basal diet
Number of subjects: 180
Study 28052513 — intervention group
Group type: EXPERIMENTAL
Intervention: Project: EVO™ (n = 12)
Number of subjects: 22
Study 28052513 — intervention group
Group type: COMPARATOR
Intervention: Problem Solving Therapy (PST, n = 10)
Number of subjects: 22
Study 25734997 — intervention group
Group type: EXPERIMENTAL
Intervention: PainCOACH (automated Internet-based pain coping skills training)
Number of subjects: 113
Study 25734997 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 113
Study 23871679 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (1mg/kg per 12h for 5 days)
Number of subjects: 76
Study 23871679 — intervention group
Group type: COMPARATOR
Intervention: Control (no progesterone)
Number of subjects: 76
Study 21707926 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone-ER (40-80 mg/day)
Number of subjects: 334
Study 19486255 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE-IFN (interferon-alpha1b at a dose of 3 million units three times a week for 48 weeks)
Number of subjects: 216
Study 19486255 — intervention group
Group type: COMPARATOR
Intervention: TACE (transarterial chemoembolization alone)
Number of subjects: 216
Study 19486255 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE-IFN
Number of subjects: 216
Study 19486255 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 216
Study 17029616 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive models using HBV DNA levels, alkaline phosphatase, albumin, and platelet counts
Number of subjects: 276
Study 17029616 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive models using age, HBV DNA levels, AST, and albumin
Number of subjects: 276
Study 17029616 — intervention group
Group type: COMPARATOR
Intervention: AST
Number of subjects: 276
Study 12941996 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 690
Study 12941996 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 690
Study 12941996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 690
Study 11579890 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil (1 tablet daily for 7 days)
Number of subjects: 16
Study 11579890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9631219 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer players
Number of subjects: 29
Study 9631219 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 29
Study 7880659 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms kg‐1 and famotidine 20 mg (n = 20)
Number of subjects: 40
Study 7880659 — intervention group
Group type: COMPARATOR
Intervention: Control group (famotidine 20 mg) (n = 20)
Number of subjects: 40
Study 7880659 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 2835200 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional prazosin (2 mg)
Number of subjects: 20
Study 2835200 — intervention group
Group type: EXPERIMENTAL
Intervention: Oros prazosin (5.5 mg)
Number of subjects: 20
Study 2835200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29909377 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 or 100 mg daily)
Number of subjects: 2536
Study 29909377 — intervention group
Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 2536
Study 27041480 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day
Number of subjects: 12705
Study 27041480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12705
Study 23642462 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 259
Study 23642462 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 259
Study 23735519 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (200 to 400mg daily for 4 weeks)
Number of subjects: 184
Study 23735519 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 4 weeks)
Number of subjects: 184
Study 20582594 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 800
Study 20582594 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 800
Study 18670333 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial branch blocks with bupivacaine (nonsteroid group)
Number of subjects: 120
Study 18670333 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical medial branch blocks with bupivacaine and steroid (steroid group)
Number of subjects: 120
Study 16855125 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored decision aid
Number of subjects: 131
Study 16855125 — intervention group
Group type: COMPARATOR
Intervention: General educational pamphlet
Number of subjects: 131
Study 12941993 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combined angiotensin-converting enzyme inhibitor and calcium channel blocker antihypertensive treatment
Number of subjects: 0
Study 12941993 — intervention group
Group type: EXPERIMENTAL
Intervention: Two preselected, fixed-dose combination therapies
Number of subjects: 0
Study 11517995 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase inhibitors
Number of subjects: 0
Study 11517995 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 9215092 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg twice daily
Number of subjects: 739
Study 9215092 — intervention group
Group type: COMPARATOR
Intervention: Aciclovir 200 mg five times daily
Number of subjects: 739
Study 8203335 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times daily
Number of subjects: 225
Study 8203335 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg three times daily
Number of subjects: 225
Study 8203335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225